ES019：Anti-SIRPα/PD-L1 BiME® Molecule to Kill Solid Tumors
Tumor-associated macrophages are major component of immune cells in the tumor micro-environment (TME) that express an array of effector molecules leading to the inhibition of anti-tumor immune responses. SIRPα is a myeloid-lineage inhibitory receptor primarily expressed on phagocytic macrophages and DCs, which inhibits phagocytosis through engagement of its ligand CD47 expressed on tumors and normal tissues.
Based on our Bispecific Macrophage Engager (BiME®) technology, we have developed a PD-L1/SIRPα bispecific antibody that is capable of reactivating macrophages and T cells to kill cancer cells. The anti-PDL1/SIRPα bispecific antibody ES019, designed for tumor cell and immune cell dual targeting, demonstrated significantly enhanced tumor therapeutic efficacy versus combo or monotherapies.
Mechanism of Action